Skip to main content
Premium Trial:

Request an Annual Quote

Abbott Again Extends Timing of Tender Offer for Alere Preferred Stock

NEW YORK (360Dx) – Abbott today said that it is extending for a second time its previously announced cash tender offer to purchase all outstanding shares of Alere's Series B convertible perpetual preferred stock at a price of $402 per share.

The offer is being made in connection to Abbott's $5.3 billion acquisition of Alere. Alere shareholders approved the acquisition in July.

The tender offer is being extended to allow additional time for the consummation of the deal, Abbott said.

The offer had initially been scheduled to expire at 11:59 p.m. EDT on Aug 11, and was extended until 11:59 p.m. EDT on Aug. 31. It will now expire at 11:59 p.m. EDT on Sept. 15.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.